louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03924375: Serum Pepsinogen After H. Pylori Eradication
Official title: Serum Pepsinogen After Helicobacter Pylori Eradication for the Gastric Cancer Prevention
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Helicobacter Pylori Eradication
Lead sponsor: Soonchunhyang University Hospital
Sponsor class: OTHER
First posted: 2019-04-23
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: H. pylori-infected subjects who underwent an upper gastrointestinal endoscopy were enrolled in this study at a single, tertiary-care, academic medical center.

Brief summary: Helicobacter pylori has been recognized as a major pathogen in gastric carcinogenesis. Current guidelines recommend the H. pylori "test-and-treat" strategy for the purpose of primary and secondary gastric cancer prevention. Considering the "point of no return" theory, however, H. pylori eradication cannot reduce the risk of gastric cancer in subjects with gastric atrophy and intestinal metaplasia. The intragastric hypoacidic environment is associated with the risk of intestinal-type gastric cancer development. Recently, the secretory ability of the stomach can be measured using the serum pepsinogen (PG) assay.

Detailed description: This study aimed to evaluate the change of serum PGs after H. pylori eradication success and identify the optimal timing of eradication.

Eligibility criteria: Inclusion Criteria:

* Gastroscopy can be performed
* Serologic markers including serum pepsinogen can be measured

Exclusion Criteria:

* Age \< 20 or \> 70 years
* Anemia (serum hemoglobin level \< 10 g/dL)
* Severe systemic disease
* Advanced chronic liver disease
* Use of certain medications, including proton pump inhibitors, H2- receptor antagonists, or antibiotics
* History of H. pylori eradication
* History of gastric surgery
* Recent history of upper gastrointestinal bleeding

Primary outcomes:
measure: Serum pepsinogen change after H. pylori eradication
timeFrame: after 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Digestive Disease Center, Soonchunhyang University Hospital
Study officials:
affiliation: Digestive Disease Center, Soonchunhyang University Hospital
name: Jun-Hyung Jun-Hyung, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04069975: Sedation Versus No Sedation for Detection Rates of Precancerous Lesions and Cancer
Official title: Sedation Versus No Sedation for Diagnostic Esophagogastroduodenoscopies and Detection Rates of Precancerous Lesions and Cancer: a Case-control Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Early Detection of Cancer
Keywords: Early Detection of cancer
Gastrointestinal Neoplasms
Endoscopy, Gastrointestinal
Lead sponsor: Shandong University
Sponsor class: OTHER
Collaborators: name: Weihai Municipal Hospital
name: Binzhou Medical University
name: Qilu Hospital of Shandong University (Qingdao)
First posted: 2019-08-28
Enrollment: 200000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: After calulating, the sample size should be more than the largest number 23,000.

As a retrospective study, the sample size may be more than 20,0000, according to our estimates.

Brief summary: The influence of sedation on the endoscopic detection rate of the precancerous lesions and cancer of upper digestive system has not been assessed. In the daily medical routine of China, patients have the right to choose the sedation style according to his or her own situation, whose detailed endoscopic data of patients are recorded in the endoscopy quality control system. The aim of this research is to detect whether the use of sedation can help improve detection rate of precancerous lesions and cancer of upper digestive system.

Detailed description: The influence of sedation on the endoscopic detection rate of the precancerous lesions and cancer of upper digestive system has not been assessed. In the daily medical routine of China, patients have the right to choose the sedation style according to his or her own situation, whose detailed endoscopic data of patients are recorded in the endoscopy quality control system. The aim of this research is to detect whether the use of sedation can help improve detection rate of precancerous lesions and cancer of upper digestive system.

Eligibility criteria: Inclusion Criteria:

* Patients aged more than 18 years with or without GI symptoms attending for endoscopy from 2012 to 2019.

Exclusion Criteria:

* Patients unable to cooperated the endoscopy or unable to complete it. People with endoscopy contraindications are naturally excluded.

Primary outcomes:
measure: Detection rate of precancerous lesions and cancer of upper digestive system improvement
timeFrame: 2020
Secondary outcomes:
Other outcomes:
Locations:
city: Jinan
country: China
facility: Department of Gastroenterology, Qilu Hospital, Shandong University
state: Shandong
Study officials:
References:
citation: Zhou J, Li Z, Ji R, Wang P, Zhang A, Wu K, Liu C, Niu Q, Chu Y, Su X, Zuo X, Li Y. Influence of Sedation on the Detection Rate of Early Cancer and Precancerous Lesions During Diagnostic Upper Gastrointestinal Endoscopies: A Multicenter Retrospective Study. Am J Gastroenterol. 2021 Jun 1;116(6):1230-1237. doi: 10.14309/ajg.0000000000001201.
Clinical trial NCT05177575: Incidence of Chronic Pain After Thoracotomy
Official title: Incidence of Chronic Pain After Thoracotomy
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Postoperative Pain
Postoperative Pain, Acute
Postoperative Pain, Chronic
Thoracotomy
Keywords: Postoperative Pain
Postoperative Pain, Acute
Postoperative Pain, Chronic
Thoracotomy
Lead sponsor: Atatürk Chest Diseases and Chest Surgery Training and Research Hospital
Sponsor class: OTHER
First posted: 2022-01-04
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients between the ages of 18-65 years, in the ASA I-II-III risk group, with a BMI between 18-35 kg/m2 and undergoing thoracotomy will be included in the study.

Patients under the age of 18 years and over the age of 65 years, with an ASA score of IV and above, with a BMI below 18 kg/m2 and above 35 kg/m2, who were operated under emergency conditions, and who received chronic pain treatment will be excluded from the study.

Brief summary: Thoracotomy is frequently performed in thoracic surgery. It is widely accepted that thoracotomy causes severe acute pain. Many factors such as postoperative analgesia treatment plan, operation time, number of chest tubes, and duration of chest tube stay can affect acute pain. This acute pain prolongs the discharge time of the patients and increases the frequency of postoperative pulmonary complications and postoperative morbidity. Postoperative acute pain may cause chronic thoracotomy pain in the later period, and may adversely affect the quality of life of the patients.

This study aims to analyze the symptoms of chronic pain in the 3rd and 6th months postoperatively in patients who had undergone thoracotomy.


Eligibility criteria: Inclusion Criteria:

* Age between 18 and 65 years
* American Society of Anesthesiologists physical status I-II-III
* Body mass index (BMI) between 18-35 kg/m2
* Patients undergoing elective thoracotomy

Exclusion Criteria:

* Advanced cancer
* History of chronic analgesic therapy
* Patients with previous thoracic surgery
* Patients who were operated under emergency conditions

Primary outcomes:
measure: Chronic pain symptoms at 3rd months.
timeFrame: Chronic pain symptoms at 3rd months.
measure: Chronic pain symptoms at 6th months.
timeFrame: Chronic pain symptoms at 6th months.
Secondary outcomes:
Other outcomes:
Locations:
city: Kecioren
country: Turkey
facility: Ankara Atatürk Chest Disease and Chest Surgery Training and Research Hospital
state: Ankara
Study officials:
affiliation: Atatürk Chest Diseases and Chest Surgery Training and Research Hospital
name: Musa Zengin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01001975: Determination of Sun Protection in Sunscreen Formulas (Study SR09-15)(P08236)(COMPLETED)
Official title: Determination of Sun Protection Factors (PFA and SPF) in Sunscreen Formulas Containing Combinations of Zinc Oxide and Avobenzone
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Sun Protection
Keywords: Sunscreens
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2009-10-27
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Study to determine the sunscreen protection factor (SPF) and ultraviolet A protection factor (PFA) of 2 sunscreen products containing the combination of zinc oxide and avobenzone with and without ensulizole.


Eligibility criteria: Inclusion Criteria:

* 18 to 70 years of age
* Have Fitzpatrick skin types I, II, or III
* In good general health based on a medical history review
* Be free of any acute or chronic illness/disease that might interfere with or increase risk of study participation
* Be able to cooperate with the investigator and research staff
* Be willing to have the test materials applied according to the protocol
* Be capable of understanding and provide written informed consent

Exclusion Criteria:

* Subjects with a history of adverse effects upon sun exposure
* Subjects currently taking any medication that may alter the sunlight response or is a known photosensitizer
* Subjects with a history of any form of cancer, lupus, psoriasis, rosacea, porphyria cutanea tarda, connective tissue disease, diabetes or any disease that would increase the risks associated with study participation
* Subjects with an abnormal sensitivity to any sunscreen agent
* Females who indicate that they are pregnant or nursing an infant during the period of the study
* Subjects with excessive hair, blemishes, nevi, warts, moles, scars, sunburn, suntan or uneven pigmentation in the test areas
* Subjects who have been administered an investigations drug or have participated in another SPF or PFA study within 30 days prior to this study
* Subjects who are allergic to latex or latex products
* Subjects who have any conditions that would make study participation inappropriate as determined by the investigator

Primary outcomes:
measure: Determination of Sunscreen Protection Factor (SPF)
timeFrame: 16 to 24 hours post-exposure
measure: Determination of Ultraviolet A Protection Factor (PFA)
timeFrame: 2 to 4 hours post-exposure
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06936059: A PRPCT to Assess the Efficacy & Safety of Chronic Pain Rehab Training Software for Alleviating Chronic Secondary Musculoskeletal Pain
Official title: A Prospective, Randomized, Parallel-controlled Clinical Trial to Evaluate the Effectiveness and Safety of Chronic Pain Rehabilitation Training Software in Assisting in the Relief of Chronic Secondary Musculoskeletal Pain
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Chronic Pain
Keywords: pain
Visual Pain Score
rehab training software
anxious
depressed
Lead sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2025-04-20
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: A prospective, randomized, parallel-controlled clinical trial to evaluate the effectiveness and safety of chronic pain rehabilitation training software in assisting in the relief of chronic secondary musculoskeletal pain

Detailed description: A PRPCT to assess the efficacy \& safety of chronic pain rehab training software for alleviating chronic secondary musculoskeletal pain

Eligibility criteria: Inclusion Criteria:

* Males and females ≥18 years old.
* Average pain intensity≥4 on a 0-10 numerical rating scale (NRS) in the past 24 hours.
* Be able to communicate in Chinese.
* Be able to read and write Chinese.
* Willing to comply with study procedures and restrictions.
* Willing and able to sign informed consent.

Exclusion Criteria:

* Shingles on the eyes, ears, head, face, or hands.
* Trigeminal neuralgia.
* Severe vision impairment. (Patients with clear vision wearing glasses or contact lenses are allowed)
* Severe hearing impairment.
* Disease or medical condition predisposing to nausea or dizziness, such as insufficient blood supply to the brain, vestibular dysfunction,cholecystitis, etc.
* History of severe motion sickness.
* Injury to eyes, ears, face, or neck that impedes comfortable use of mixed reality.
* Injury or dysfunction of hands or upper limbs that impedes comfortable use of mixed reality.
* Diagnosis of cognitive impairment, epilepsy, dementia, migraines or other neurological diseases that may prevent the use of mixed reality.
* History of mental illness, including depression, generalized anxiety disorder, schizophrenia, etc.
* Females currently pregnant.
* Current or completion of participation within 4 weeks before screening in any interventional clinical study
* Patients whom the investigator considers not suitable to participate in this study.

Primary outcomes:
measure: Change in pain intensity before and after MR therapy
timeFrame: 20min
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Xinhua hospital ,Shanghai Jiaotong University, School of medicine
state: Shanghai
Study officials:
References:
Clinical trial NCT00568659: The Specific Lung Elastance in Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) Patients in Supine and Prone Position
Official title: The Specific Lung Elastance in ALI/ARDS Patients in Supine and Prone Position
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Lung Injury
Acute Respiratory Distress Syndrome
Keywords: Gas exchange
Respiratory mechanics
Ventilator Induced Lung Injury
Lead sponsor: Policlinico Hospital
Sponsor class: OTHER
First posted: 2007-12-06
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The investigators aim is to study the specific lung elastance in ALI/ARDS patients during invasive mechanical ventilation, in supine and prone position.

Detailed description: In sedated and paralyzed ALI/ARDS patients, we study and compare the specific lung elastance in supine and prone position during invasive mechanical ventilation.

Eligibility criteria: Inclusion Criteria:

* ALI/ARDS patients during invasive mechanical ventilation

Exclusion Criteria:

* Haemodynamic failure, pneumothorax

Primary outcomes:
measure: Specific elastance
timeFrame: 5 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Milano
country: Italy
facility: Policlinico Hospital
Study officials:
affiliation: Policlinico Hospital
name: Davide Chiumello, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03089359: Prehospital Recognition and Identification of Unspecific Symptoms
Official title: Prehospital Recognition and Identification of Unspecific Symptoms
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Serious Condition
Morality
Keywords: Unspecific symptoms
Soluvent urokinase plasminogen activator receptor
Lactate
Emergency Medical Services
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
First posted: 2017-03-24
Enrollment: 414
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Unspecific symptoms presenting to the EMS

Brief summary: This study evaluates the predictive value of soluvent urokinase plasminogen activator receptor (suPAR) and lactate with respect to serious conditions among patients presenting to the EMS with unspecific symptoms.


Eligibility criteria: Inclusion Criteria:

* Unspecific symptoms (not feeling well, decreased general health condition, unable to cope with usual daily activities, feeling weak)
* Normal vital signs
* Transported to ED
* Able to give informed consent/ Next of kin gives informed consent

Exclusion Criteria:

* Specific symptoms
* under 18 years of age
* Stays home / other caregiver than ED
* Referral from caregiver
* No personal numer (social security number)

Primary outcomes:
measure: Serious condition
timeFrame: During medical care event
Secondary outcomes:
measure: Mortality
timeFrame: 24hours and 30 days
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: Helsinki University
city: Stockholm
country: Sweden
facility: Karolinska Institute
Study officials:
affiliation: Karolinska Institutet
name: Katarina Bohm, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ivic R, Nurmi J, Kurland L, Vicente V, Lindstrom V, Djarv T, Kaartinen J, Castren M, Bohm K. Soluble urokinase plasminogen activator receptor and lactate as prognostic biomarkers in patients presenting with non-specific chief complaints in the pre-hospital setting - the PRIUS-study. Scand J Trauma Resusc Emerg Med. 2021 Aug 12;29(1):116. doi: 10.1186/s13049-021-00908-z.
Clinical trial NCT00502359: Testing Ascensia Contour Glucometer for the Measurement of Blood Glucose
Official title: Testing Ascensia Contour Glucometer for the Measurement of Blood Glucose Values in Pregnancy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gestational Diabetes
Keywords: Gestational diabetes, screening, glucose monitoring
Lead sponsor: University of Zurich
Sponsor class: OTHER
Collaborators: name: Bayer
First posted: 2007-07-17
Enrollment: 2005
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: Present practice: Measurement of fasting glucose values in 2nd trimester of pregnancy, if above 4.8 mmol/l, a Glucose Tolerance Test is performed. (Two-step procedure: 1. Appointment for the fasting glucose measurement, 2. Appointment for the Glucose Tolerance Test)

Detailed description: Present practice: Measurement of fasting glucose values in 2nd trimester of pregnancy, if above 4.8 mmol/l, a Glucose Tolerance Test is performed. (Two-step procedure: 1. Appointment for the fasting glucose measurement, 2. Appointment for the Glucose Tolerance Test) Study: Testing of reliability and applicability of the Ascensia Contour Glucometer, Bayer. Comparison of 100 fasting glucose values measured in venous plasma by the hexokinase method in the Laboratory with 100 fasting glucose values measured in capillary whole blood on the Ascensia Contour Glucometer Outcome: If Ascensia Contour Glucometer shows applicable accuracy (narrow scatter of values), the two-step procedure should be replaced by one-step procedure: 1 only one appointment for the measurement of the fasting glucose value in capillary whole blood on Ascensia Contour Glucometer and if above 4.8 mmol/l Glucose Tolerance Test on the same day

Eligibility criteria: Inclusion criteria:

* Healthy pregnant women in 2nd Trimester of pregnancy scheduled for the measurement of fasting glucose value

Exclusion criteria:

* Pregnant women with pre-existent (Type 1 or 2) diabetes or already diagnosed diabetes of pregnancy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: Clinic of obstetrics, University Hospital of Zurich
Study officials:
affiliation: UniversitaetsSpital Zuerich
name: 01 Studienregister MasterAdmins
role: STUDY_DIRECTOR
References:
Clinical trial NCT03944759: Efficacy of Serratus Anterior Plane Block Mastectomy
Official title: Efficacy of Serratus Anterior Plane Block Using Bupivacaine/Magnesium Sulphate Versus Bupivacaine/Nalbuphine for Mastectomy: a Randomized Double Blinded Comparative Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Pain
Postoperative Complications
Lead sponsor: Beni-Suef University
Sponsor class: OTHER
First posted: 2019-05-10
Enrollment: 40
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Breast cancer is the main common cancer among females. . Inadequate control of pain may later develop into chronic pain syndrome (paraesthesias, phantom breast pain, and intercostobrachial neuralgia) in 25-40% of the patients .

Detailed description: The aim of this study is to compare the efficacy of ultrasound-guided serratus anterior plane block with bupivacaine/ magnesium versus bupivacaine/ nalbuphine in breast cancer surgery.

Patients and methods nclusion criteria:

-ASA I and II female patients, age 25-60 undergoing breast cancer surgery

Exclusion criteria:

* Patient refusal
* Contraindications for regional blocks (eg. Infection at the injection site, coagulopathy)
* Allergy to the drugs used in the study
* Chronic pain therapy,
* BMI more than 30 kg/m2

Eligibility criteria: Inclusion Criteria:

* ASA I and II female patients, age 25-60 undergoing breast cancer surgery

Exclusion Criteria:

* -Patient refusal
* Contraindications for regional blocks (eg. Infection at the injection site, coagulopathy)
* Allergy to the drugs used in the study
* Chronic pain therapy,
* BMI more than 30 kg/m2

Primary outcomes:
measure: time to first analgesic requirements in minutes
timeFrame: change from base line for 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Banī Suwayf
country: Egypt
facility: Faculty Of Medicine, Beni-Suef University
Study officials:
affiliation: Faculty of Medicine Beni-Suef University
name: Doaa Rashwan, MD
role: STUDY_DIRECTOR
References: